Aethlon Medical (NASDAQ:AEMD) Stock Price Passes Below 200-Day Moving Average – Here’s Why

Aethlon Medical, Inc. (NASDAQ:AEMD) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.35 and traded as low as $1.35. Aethlon Medical shares last traded at $1.36, with a volume of 140,847 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Aethlon Medical Price Performance

The business has a 50 day moving average price of $2.16 and a 200 day moving average price of $2.35. The firm has a market capitalization of $3.22 million, a P/E ratio of -0.09 and a beta of 1.49.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent quarter. 1.99% of the stock is currently owned by institutional investors and hedge funds.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.